СИСТЕМНАЯ СКЛЕРОДЕРМИЯ С ИНТЕРСТИЦИАЛЬНЫМПОРАЖЕНИЕМ ЛЕГКИХ: СРАВНИТЕЛЬНАЯ КЛИНИЧЕСКАЯХАРАКТЕРИСТИКА С БОЛЬНЫМИ БЕЗ ПОРАЖЕНИЯ ЛЕГКИХ
https://doi.org/10.14412/1995-4484-2010-442
Аннотация
Об авторах
Lyudmila Valeryevna TeplovaЛ. П. Ананьева
V N Lesnyak
М. Н. Старовойтова
О. В. Денисова
Т. А. Невская
Елена Николаевна Александрова
Список литературы
1. <div><p>Гусева Н.Г. Системная склеродермия и псевдосклеродермические синдромы. М.: Медицина, 1993;75-82.</p><p>Steen V.D., Medsger T.A. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthr Rheum 2000;43:2437-44.</p><p>Ferri C., Valentini G., Cozzi F. et al. Systemic Sclerosis Study Group of the Italian Society of Rheumatology (SIRGSSSc). Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine (Baltimore) 2002;81(2):139-53.</p><p>Steen V.D. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 2007;66(7):940-4.</p><p>Weaver A.L., Divertie M.B., Titus J.L. Pulmonary scleroderma. Dis Chest 1968;54(6):490-8.</p><p>Невская Т.А., Новиков А.А., Александрова Е.Н. и др. Клиническое значение высокочувствительного С-реактивного белка при системной склеродермии. Науч-практич ревматол 2007;4:10-7.</p><p>Steen V. Predictors of end stage lung disease in systemic sclerosis. Ann Rheum Dis 2003;62(2):97-9.</p><p>Kusume K. Lung injury in idiopathic pulmonary fibrosis and measurement of immunoreactive neutrophil elastase and alpha 1-protease inhibitor in blood. Nihon Kyobu Shikkan Gakkai Zasshi 1991;29(10):1254-60.</p><p>LeRoy E.C., Black C., Fleischmajer R. et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15(2):202-5.</p><p>Valentini G., Della Rossa A.,Bombardieri S. et al. European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indexes. Ann Rheum Dis 2001;60(6):592-8.</p><p>Тюрин И.Е. Компьютерная томография органов грудной полости. СПб.: ЭЛБИ, 2003;324-30.</p><p>Schurawitzki H., Stiglbauer R.,Graninger W. et al. Interstitial lung disease in progressive systemic sclerosis: high-resolution CT versus radiography. Radiology 1990;176(3):755-9.</p><p>Afeltra A., Zennaro D., Garzia P. et al. Prevalence of interstitial lung involvement in patients with connective tissue diseases assessed with high-resolution computed tomography. Scand J Rheumatol 2006;35(5):388-94.</p><p>De Santis M., Bosello S., La Torre G. et al. Functional, radiological and biological markers of alveolitis and infections of the lower respiratory tract in patients with systemic sclerosis. Respir Res 2005;17(6):96.</p><p>Goldin J.G., Lynch D.A., Strollo D.C. et al. High-resolution CT scan findings in patients with symptomatic sclerodermarelated interstitial lung disease. Chest 2008;134(2):358-67.</p><p>Ooi G.C., Mok M.Y., Tsang K.W. et al. Interstitial lung disease in systemic sclerosis. Acta Radiol 2003;44(3):258-64.</p><p>Clements P.J., Roth M.D., Elashoff R. et al. Scleroderma lung study (SLS): differences in the presentation and course of patients with limited versus diffuse systemic sclerosis. Ann Rheum Dis 2007;66(12):1641-7.</p><p>McNearney T.A., Reveille J.D.,Fischbach M. et al. Pulmonary involvement in systemic sclerosis: associations with genetic, serologic, sociodemographic, and behavioral factors. Arthr Rheum 2007;15;57(2):318-26.</p><p>Quadrelli S.A., Molinari L., Ciallella L.M. et al. Patterns of pulmonary function in smoking and nonsmoking patients with progressive systemic sclerosis. Rheumatol Int 2009;29(9):995-9.</p><p>Warrick J.H., Bhalla M., Schabel S.I. High resolution computed tomography in early scleroderma lung disease. J Rheumatol 1991;18(10):1520-8</p><p>Мониторинг состояния здоровья населения Российской Федерации. Российский мониторинг экономического положения и здоровья населения 1992- 2001 гг. Университет Северной Каролины в Чэпел Хилле и Институт социологии РАН, 2002.</p><p>Witt C., Borgess A.C., John M. et al. Pulmonary involvement in difuse cutaneous systemic sclerosis:bronchoalveolar fluid granulocytosis predicts progression of fibrosing alveolitis. Ann Rheum Dis 1999;58:635-40.</p><p>Shahin A.A., Sabri Y.Y., Mostafa H.A. et al. Pulmonary function tests, high-resolution computerized tomography, alpha1-antitrypsin measurement, and early detection of pulmonary involvement in patients with systemic sclerosis. Rheumatol Int 2001;20(3):95-100.</p><p>Caccavo D., Afeltra A., Rigon A. et al. Antibodies to carbonic anhydrase in patients with connective tissue diseases: relationship with lung involvement. Int J Immunopathol Pharmacol 2008;21(3):659-67.</p><p>Bryan C., Knight C., Black C.M. et al. Prediction of five-year survival following presentation with scleroderma: development of a simple model using three disease factors at first visit. Arthr Rheum 1999;42(12):2660-5.</p><p>Nagy Z., Czirjak L. Increased levels of amino terminal propeptide of type III procollagen are an unfavourable predictor of survival in systemic sclerosis. Clin Exp Rheumatol 2005;23(2):165-72.</p><p>Kanoh S., Kobayashi H., Motoyoshi K. et al. Exhaled ethane: an in vivo biomarker of lipid peroxidation in interstitial lung diseases. Chest 2005;128(4):2387-92.</p><p>Tajima S., Oshikawa K., Tominaga S. et al. The increase in serum soluble ST2 protein upon acute exacerbation of idiopathic pulmonary fibrosis. Chest 2003;124(4):1206-11.</p><p>Goh N.S., Veeraraghavan S., Desai S.R. et al. Bronchoalveolar lavage cellular profiles in patients with systemic sclerosis-associated interstitial lung disease are not predictive of disease progression. Arthr Rheum 2007;56(6):2005-12.</p><p>Strange C., Bolster M.B., Roth M.D. et al. Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung disease. Am J Respir Crit Care Med 2008;177(1):91-8.</p><p>Rizou C., Ioannidis J.P., Panou-Pomonis E. et al. B-Cell epitope mapping of DNA topoisomerase I defines epitopes strongly associated with pulmonary fibrosis in systemic sclerosis. Am J Respir Cell Mol Biol 2000;22(3):344-51.</p><p>Jacobsen S., Ullman S., Shen G.Q. et al. Influence of clinical features, serum antinuclear antibodies, and lung function on survival of patients with systemic sclerosis. J Rheumatol 2001;28(11):2454-9.</p><p>Geirsson A.J., Wollheim F.A., Akesson A. Disease severity of 100 patients with systemic sclerosis over a period of 14 years: using a modified Medsger scale. Ann Rheum Dis 2001;60(12):1117-22.</p><p>Latsi P.I., Wells A.U. Evaluation and management of alveolitis and interstitial lung disease in scleroderma. Curr Opin Rheumatol 2003;15(6):748-55.</p></div><br />
Рецензия
Для цитирования:
Teplova L.V., Ананьева Л.П., Lesnyak V.N., Старовойтова М.Н., Денисова О.В., Невская Т.А., Александрова Е.Н. СИСТЕМНАЯ СКЛЕРОДЕРМИЯ С ИНТЕРСТИЦИАЛЬНЫМПОРАЖЕНИЕМ ЛЕГКИХ: СРАВНИТЕЛЬНАЯ КЛИНИЧЕСКАЯХАРАКТЕРИСТИКА С БОЛЬНЫМИ БЕЗ ПОРАЖЕНИЯ ЛЕГКИХ. Научно-практическая ревматология. 2010;48(3):41-47. https://doi.org/10.14412/1995-4484-2010-442
For citation:
Teplova L.V., Ananyeva L.P., Lesnyak V.N., Starovoitova M.N., Desinova O.V., Nevskaya T.A., Aleksandrova E.N. SCLERODERMA SYSTEMATICA WITH INTERSTITIAL LUNG LESION: COMPARATIVE CLINICAL CHARACTERISTICSWITH PATIENTS WITHOUT LUNG LESION. Rheumatology Science and Practice. 2010;48(3):41-47. (In Russ.) https://doi.org/10.14412/1995-4484-2010-442
Просмотров: 756
Послать статью по эл. почте 